retatrutide mechanism triple agonist gip glp-1 glucagon receptor LY3437943, a novel glucagon, GIP, and for glycemic control and weight loss: From discovery to clinical proof of concept PDB-101: Molecule of the Month:

This slow-and-steady approach is essential for supporting patient comfort and adherence

Drug Interactions Can Be Dangerous GLP-1 medications can interact with other drugs you're already taking, including medications for diabetes, blood pressure, and other chronic conditions

When you eat, your blood sugar levels begin to rise, and this rise is more dramatic in people with type 2 diabetes

Clinical trials showed folks could lose 15-20% of their body weight with these, plus lifestyle changes

These are promising results, but the studys authors note that more research is needed, and clinicians must also consider potential adverse effects, evaluate the cost-effectiveness of these medications for each patient, and closely monitor for any improvement or worsening of eating disorders and related side effects. That hesitation is shared by the National Eating Disorder Association (NEDA), who published an opinion paper on GLP-1s and eating disorders in 2024, stating: While there is some evidence that GLP-1s can decrease the number of binge eating episodes for those with BED, little is known about the long term physical and psychological impact on those with eating disorders. How GLP-1s could also fuel eating disorders The same mechanisms that make these medications helpful for some could make them harmful for others

The bad news is that for the foreseeable future, consumers will continue to pay high prices, and employers are likely to continue to be more circumspect about coverage